Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
Leerink Lowers PT after Ironwood Pharmaceuticals (IRWD) 1Q Results
May 6, 2015 11:00 AM EDTLeerink Partners reiterates a Market Perform rating on Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and lowers its price target to $16 (from $17) after weak 1Q sales. The Linzess profit share fell short of street expectations due to challenging sales, and seasonality, the analyst notes
Leerink analyst... More
Ironwood Pharma (IRWD) Reports Q1 Lost Per Share of 24c
May 5, 2015 5:07 PM EDTIronwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.24), may note compare the analyst estimate of ($0.23). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $32.3 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More


